LEADER 01533nam  2200421Ia 450 
001 9910698801903321
005 20090608152442.0
035   $a(CKB)5470000002397852
035   $a(OCoLC)374880861
035   $a(EXLCZ)995470000002397852
100   $a20090608d2009      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $esomatic cell therapy for cardiac disease
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research :$cCenter for Devices and Radiological Health,$d[2009]
215   $aii, 22 p $cdigital, PDF file
300   $aTitle from PDF title page (viewed on June 8, 2009).
300   $a"Draft guidance".
300   $a"March 2009".
320   $aIncludes bibliographical references (page 19).
517   $aGuidance for industry 
606   $aSomatic cells
606   $aCellular therapy$xGovernment policy$zUnited States
606   $aHeart$xDiseases$zUnited States
615  0$aSomatic cells.
615  0$aCellular therapy$xGovernment policy
615  0$aHeart$xDiseases
712 02$aCenter for Biologics Evaluation and Research (U.S.)
712 02$aCenter for Devices and Radiological Health (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698801903321
996   $aGuidance for industry$93434577
997   $aUNINA